Wall Street Journal |
Eli Lilly Alzheimer's Drug Fails Trial
Wall Street Journal Alzheimer's is a progressive form of dementia that causes memory, thinking and behavioral problems with symptoms worsening as someone ages. Phase 3 clinical trials are typically the last phase before a drug seeks approval from the Food and Drug … Hopes for new Alzheimer's drug dashed Lilly's solanezumab flunks late-stage study in Alzheimer's-related dementia; shares down 14% premarket; Biogen … Eli Lilly Shares Plunge as Alzheimer's Trial Fails to Achieve Goals |
